Stock Analiz

Pacific Biosciences OF California, Inc. PACB

Biotechnology: Laboratory Analytical Instruments · IPO 2010 · data as of November 13, 2026

$1.96Market cap $613M
Open the interactive analysis →

Pacific Biosciences OF California, Inc. (PACB) is a industrial company listed in the US with a market value of about $613M. In the twelve months to September 30, 2026 it had revenue of $161M and net income of -$131M, a net margin of -81.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 15% a year, a 5-year average ROIC of -169%.

About Pacific Biosciences OF California

Pacific Biosciences OF California is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2010. Revenue went from $61M in 2014 to $160M in 2025, growth of about 9.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 34% over three years (dilution for shareholders). It spends 61% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.8
P/B—
EV/EBITDA1.9
PEG—
Dividend yield0.00%
FCF yield-23.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)3.9%
Revenue growth (5 yrs, per year)15.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-215.9%
ROIC (5-yr avg.)-168.7%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$161M$160M$154M$201M$128M$131M$79M$91M$79M$93M$91M
Net income-$131M-$546M-$310M-$307M-$314M-$181M$29M-$84M-$103M-$92M-$74M
Free cash flow-$143M-$114M-$212M-$268M-$280M-$117M$18M-$81M-$68M-$78M-$76M
EPS (diluted)$-0.42$-1.82$-1.59$-1.21$-1.40$-0.89$0.17$-0.55$-0.76$-0.87$-0.83
Net margin-81.3%-341.5%-201.2%-153.0%-244.9%-138.8%37.3%-92.6%-130.4%-98.6%-82.0%
ROIC—-701.3%-70.5%-43.4%-20.3%-8.0%-21.9%-68.0%-44.8%-71.1%-55.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 7 analysts is $2.74, 40% above the current price; targets range from $2.00 to $3.00; the consensus rating is “Buy”; expected EPS is $-0.49 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Pacific Biosciences OF California pay a dividend?

Not currently.

Is Pacific Biosciences OF California a good stock to buy?

We do not give buy or sell advice. Pacific Biosciences OF California scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.